Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05660447 · ClinicalTrials.gov registry record · Phase 2
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
A Phase 2 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, sponsored by Wills Eye.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05660447 is a Phase 2 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy that is active but no longer recruiting, run by Wills Eye. The registered enrollment target is 80 participants, below the 359-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05660447, a Phase 2 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, is active but no longer recruiting, sponsored by Wills Eye.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if a drug called netarsudil is safe and able to prevent the development of scar tissue after retinal detachment repair. Patients eligible for this study are those diagnosed with a rhegmatogenous retinal detachment deemed at high risk for scar tissue formation (a process called 'proliferative vitreoretinopathy').
Conditions Studied
Interventions
- DRUG Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
- DRUG Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Study Locations (1)
Pennsylvania
- Wills Eye Physicians - Mid Atlantic Retina - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05660447
The ClinicalTrials.gov registry entry for NCT05660447 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 359-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (78% lower). The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rhegmatogenous Retinal Detachment appearing as the primary indexed condition, and to 2 interventions - of which Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] is the first listed.
NCT05660447 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05660447 about?
NCT05660447 is a clinical study titled "A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR". The purpose of this study is to determine if a drug called netarsudil is safe and able to prevent the development of scar tissue after retinal detachment repair. Patients eligible for this study are those diagnosed with a rhegmatogenous retinal detachment deemed at high risk for scar tissue formatio...
What is the current status of trial NCT05660447?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-02-06. Estimated completion is 2025-01-31.
What conditions does trial NCT05660447 study?
This clinical trial studies the following conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy.
What interventions are being tested in trial NCT05660447?
The interventions under investigation include: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] (DRUG), Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud (DRUG).
Who is sponsoring clinical trial NCT05660447?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05660447 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhegmatogenous Retinal Detachment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
RECRUITING · Phase 2
-
Dropless Pars Plana Vitrectomy Study
RECRUITING · Phase 4
-
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
RECRUITING · Phase 1
Explore more on PlainTrial
Rhegmatogenous Retinal Detachment
All registered trials for this condition
Proliferative Vitreoretinopathy
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.